ERCP PEP Risk • Prophylaxis Eligibility
Pre-Procedural & Procedural Factors
Select patient and procedural risk factors to determine complication profile.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Pre-procedural risk assessment for patients undergoing ERCP
To guide the decision for prophylactic rectal NSAIDs or pancreatic duct (PD) stenting
To aid in the informed consent process by quantifying patient-specific risks
Defining PEP
Post-ERCP Pancreatitis is defined as new or worsened abdominal pain with amylase/lipase ≥ 3x ULN at 24 hours post-procedure, requiring at least 2 days of unplanned hospitalization.
How it Works
High-Risk Patient Factors
Young age (typically < 50 years)
Female sex
Suspected Sphincter of Oddi Dysfunction (SOD)
History of prior post-ERCP pancreatitis
Normal Total Bilirubin (correlates with small CBD diameter)
High-Risk Procedural Factors
Difficult cannulation (e.g., > 10 attempts or > 10 minutes)
Pancreatic duct (PD) cannulation or contrast injection
Pre-cut sphincterotomy (especially if performed by trainee)
Biliary balloon sphincteroplasty (without sphincterotomy)
The Cumulative Effect
Risk is synergistic. A young female with SOD undergoing a difficult cannulation has a PEP risk approaching 30%, compared to a baseline risk of ~5% in the general population.
Clinical Pearls
Prevention Strategy — Rectal NSAIDs
Universal administration of 100mg Rectal Indomethacin (or Diclofenac) pre- or immediately post-ERCP is now a Tier-1 quality metric (ESGE/ASGE). It reduces the relative risk of PEP by approximately 40–50%.
PD Stenting vs. NSAIDs
In extremely high-risk cases (e.g., repeated PD cannulation), rectal NSAIDs alone may be insufficient. Placement of a 3Fr or 5Fr prophylactic pancreatic stent is the gold standard for high-risk prevention.
Clinical Pearls
Aggressive periprocedural hydration (Lactated Ringers) reduces PEP severity but not necessarily incidence
Small CBD diameter (< 5mm) is an independent technical risk factor for "difficult" cannulation and PEP
Double-wire technique for biliary access increases PEP risk unless a PD stent is placed
Next Steps
Post-Procedure Action
01
Patient has ≥ 2 High-Risk Factors: Mandatory Rectal Indomethacin and consider 4-hour post-ERCP Amylase check.
02
Amylase at 4h < 1.5x ULN: Excellent negative predictive value (NPV); patient is likely safe for same-day discharge.
03
Significant Post-Op Pain: Admit for observation and IV hydration; do not wait for lipase to rise.
The Evidence
Core Risk Factors study
Risk factors for post-ERCP pancreatitis: a prospective, multicenter study.
Freeman ML et al. • Gastrointestinal Endoscopy. 2001;54(4):425-34. Large-scale multicenter study defining modern risk groups.
View Source• . ;
The NSAID Trial (Elmunzer)
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis.
Elmunzer BJ et al. • N Engl J Med. 2012;366(15):1414-22. The landmark trial establishing rectal NSAIDs as standard of care.
View SourceOrigins & History
The Indianapolis-Minnesota Consensus
The primary risk factors were refined through collaborative research led by Martin Freeman (Minnesota) and Greg Lehman (Indianna). Their work moved ERCP from an "unpredictable" procedure to one where high-risk subsets could be identified and protected through advanced stenting and pharmacotherapy.
Last Comprehensive Review: 2026-07-17